The company's low ROE and stagnant net income growth over th...
The company's low ROE and stagnant net income growth over the past five years are worrisome. Despite high profit retention, the low return rate may be hindering earnings growth. The market seems to overlook the company's positive fundamentals, focusing more on the negatives.
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment